In particular, since the majority of clinical trials on the anticancer activity of Lf have been conducted in patients with lung and colorectal cancer [22,23,24], ascertaining whether this proton pump is a reliable biomarker for Lf treatment decisions in these two cancer cell types would contribute to validate this possibility. This evidence concerns the gene LTF and cancer.